MIRA Pharmaceuticals Reaffirms Going Concern, Reports Reduced Net Loss and Extended Cash Runway into Q1 2027

summarizeSummary

MIRA Pharmaceuticals filed its Q1 2026 report, reaffirming its going concern status but showing improved financial performance with a reduced net loss and increased R&D, extending its cash runway into Q1 2027.

check_boxKey Events

• Going Concern Reaffirmed with Extended Runway

  The company reiterated its going concern warning, stating it has insufficient cash for 12 months, but updated its cash runway to extend into at least the first quarter of 2027. Cash on hand as of March 31, 2026, was $4.8 million.

• Reduced Net Loss and Increased R&D

  MIRA Pharmaceuticals reported a net loss of $1.15 million for Q1 2026, a significant improvement from $1.78 million in Q1 2025. Research and development expenses increased to $524,781 from $314,404 year-over-year, indicating continued investment in its pipeline.

• Repayment of Related-Party Advance

  The company repaid a $330,607 advance payable to its Chairman and CEO, Erez Aminov, during Q1 2026, reducing related-party liabilities.

• CEO Awarded RSUs for Clinical Milestone

  CEO Erez Aminov was issued 83,500 fully vested Restricted Stock Units (RSUs) valued at $86,005, following the achievement of a Phase 1 clinical trial milestone for one of the company's drug candidates.

auto_awesomeAnalysis

This quarterly report provides an updated financial picture for MIRA Pharmaceuticals, reiterating the previously disclosed going concern warning. While the company continues to face liquidity challenges, it reported a significantly reduced net loss and increased research and development spending, alongside a repayment of related-party debt. The updated cash runway into Q1 2027 offers a clearer, albeit still short-term, outlook on its financial viability. Investors should monitor future capital raising efforts and clinical trial progress.